首页> 美国卫生研究院文献>Radiology and Oncology >18FFDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

【2h】

18FFDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

机译：18F FDG宠物免疫疗法辐射瘤签名（IRADIOMICS）预测斑洛洛瑞司治疗非小细胞肺癌患者的反应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [ F]FDG PET radiomics signature (iRADIOMICS) predicts response of metastatic non-small-cell lung cancer (NSCLC) patients to pembrolizumab better than the current clinical standards.

机译：免疫检查点抑制剂改变了癌症治疗的范式;然而，仍然需要反应的非侵入性生物标志物来确定非响应者的候选人。我们的旨在调查免疫治疗[F] FDG宠物辐射瘤签名（IRADIOMICS）预测转移性非小细胞肺癌（NSCLC）患者的响应优于目前的临床标准。

著录项

期刊名称 Radiology and Oncology
作者
Damijan Valentinuzzi; Martina Vrankar; Nina Boc; Valentina Ahac; Ziga Zupancic; Mojca Unk; Katja Skalic; Ivana Zagar; Andrej Studen; Urban Simoncic; Jens Eickhoff; Prof. Robert Jeraj;
展开▼
作者单位

展开▼
年(卷),期 2020(54),3
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
anti-PD-1;

相似文献

外文文献
中文文献
专利

1. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab [J] . Damijan Valentinuzzi, Martina Vrankar, Nina Boc, Radiology and Oncology . 2020,第3期

机译：[18F] FDG宠物免疫疗法辐射瘤签名（IRADIOMICS）预测斑洛洛瑞司治疗非小细胞肺癌患者的反应
2. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells [J] . Roger Sun, Nora Sundahl, Markus Hecht, Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：用CD8细胞验证签名预测用免疫疗法治疗癌症治疗癌症患者的结果和俯视反应的辐射瘤
3. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker [J] . Bingxi He, Di Dong, Yunlang She, Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：用肿瘤突变覆荷射系生物标志物预测对晚期非小细胞肺癌免疫疗法的反应
4. Radiomics Biomarkers from PET/CT Multi-modality Fusion Images for the Prediction of Immunotherapy Response in Advanced Non-small Cell Lung Cancer Patients [C] . Wei Mu, Jin Qi, Hong Lu, SPIE Medical Imaging Conference . 2018

机译：PET / CT多模态融合图像的放射性标记生物标志物用于预测晚期非小细胞肺癌患者的免疫治疗反应
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells [O] . Roger Sun, Nora Sundahl, Markus Hecht, 2020

机译：用CD8细胞验证签名预测用免疫疗法治疗癌症治疗癌症患者的结果和俯视反应的辐射瘤
7. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker [O] . Bingxi He, Di Dong, Yunlang She, 2020

机译：用肿瘤突变覆荷射系生物标志物预测对晚期非小细胞肺癌免疫疗法的反应

18FFDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

摘要

著录项

相似文献

相关主题

期刊订阅